Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin

BACKGROUND: The most recent treatment guidelines for type 2 diabetes (T2D) recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors should be considered preferentially in patients with T2D with either a high cardiovascular risk or with cardiovascular disease (CVD), regardless of their diabetes st...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shimabukuro, Michio, Teragawa, Hiroki, Okada, Yosuke, Takamura, Toshinari, Taguchi, Isao, Toyoda, Shigeru, Tomiyama, Hirofumi, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325864/
https://www.ncbi.nlm.nih.gov/pubmed/34332584
http://dx.doi.org/10.1186/s12933-021-01352-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325864/
https://www.ncbi.nlm.nih.gov/pubmed/34332584
http://dx.doi.org/10.1186/s12933-021-01352-0

Ejemplares similares